English Français

Medexus Pharmaceuticals, Inc. Medexus Pharmaceuticals, Inc.

  • English
  • About
    • Overview
    • Growth Strategy
    • Management Team
    • Board of Directors
  • Our Portfolio
    • Overview
    • Canadian Product Portfolio
    • US Product Portfolio
  • News
    • Press Releases
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Presentation
    • Financial Results
    • Stock Data
    • Governance
    • SEDAR+
  • Contact
  • Careers
  • English
  • Français

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
    • 2023 Annual Meeting
    • 2022 Annual Meeting
    • 2021 Annual Meeting
    • 2020 Annual Meeting
    • 2021 Special Meeting
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Presentation
  • Financial Results
  • Stock Data
    • TSX: MDP
    • OTCQX: MEDXF
    • Analyst Coverage
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEDAR+
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
  • 2023 Annual Meeting
  • 2022 Annual Meeting
  • 2021 Annual Meeting
  • 2020 Annual Meeting
  • 2021 Special Meeting
Mar 08, 2021 8:30am EST

Medexus to Participate in the 33rd Annual ROTH Conference on March 15-17, 2021

Mar 01, 2021 5:00pm EST

Medexus Achieves Record Revenue of $31.5 Million for the Third Quarter Fiscal 2021

Feb 25, 2021 9:00am EST

Medexus Announces Expanded Availability of Gleolan® in Canada

Feb 24, 2021 9:00am EST

Medexus Schedules Third Quarter Fiscal 2021 Conference Call

Feb 23, 2021 8:51am EST

Medexus Announces Closing of $32.5 Million Public Offering, Including Exercise in Full of Over-Allotment Option

Feb 16, 2021 4:43pm EST

Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side

Feb 03, 2021 10:10am EST

Medexus Announces Upsize to Previously Announced Bought Deal Public Offering

Feb 02, 2021 3:03pm EST

Medexus Announces $20 Million Bought Deal Public Offering of Units

Feb 02, 2021 2:21pm EST

Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic Stem Cell Transplantation, Treosulfan, in the United States

Jan 25, 2021 8:30am EST

Medexus Announces Renewal and Expansion of Canadian Distribution Agreement for NYDA®

RSS
  • Previous
    • 1...
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • ...15
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
    © 2023 Medexus Pharmaceuticals, Inc.
    All Rights Reserved.
    Facebook Facebook
    Privacy Policy Disclaimer Sitemap

    Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.